Dr. Matthew Weiss presents data on patient organoids & cancer care at the American Surgical Association annual meeting
Milltrust Ventures will also assist Oncoshot with its expansion in Australia and India, where the latter has already established partnerships amongst apex cancer institutes
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
Subscribe To Our Newsletter & Stay Updated
